A study in the 'Current Medical Research and Opinion' journal depicted that Pregabalin significantly improves pain and sleep quality, without a clinically meaningful difference between diabetes types.

Parsons B and his colleagues performed this study to compare pregabalin's efficacy and safety for painful diabetic peripheral neuropathy (pDPN) in people with type 1 (T1DM) or 2 diabetes mellitus (T2DM).

The pooled data from 10 randomized clinical trials (pregabalin-treated T1DM and T2DM subjects with pDPN). They were examined for change in baseline (CFB) scores (pain and sleep disturbance) applying the mixed model repeated measures (MMRM) through Week 12 and last observation carried forward (LOCF). The adverse events (AEs) were noted.

Total 1788 Pregabalin-treated (T1DM 156 [8.7%]; T2DM 1632 [91.3%]) and total 960 placebo subjects (T1DM 92 [9.6%]; T2DM 868 [90.4%]) had comparable baseline demographic characteristics between treatment groups within the same diabetes type. The T2DM (vs T1DM) subjects were 10 years older. The  mean±SD baseline pain (T1DM: 6.2±1.4 and 6.5±1.6; T2DM: 6.5±1.5 and 6.4±1.5) and sleep scores (T1DM: 5.2±2.4 and 5.2±2.7; T2DM: 5.3±2.5 and 5.1±2.5) were comparable in pregabalin and placebo. The mean CFB treatment differences (pregabalin minus placebo) were significantly dissimilar for pain and sleep with either diabetes types (all weeks p<0.05). Pregabalin's odds ratios (ORs) of achieving 30% pain reduction were similar with T2DM  and T1DM using LOCF. Pregabalin's ORs of 30% improvement in sleep quality was 1.81 (95% CI, 1.06, 3.09) with T1DM and 2.01 (1.69, 2.39) with T2DM (both p<0.05). The AEs were in accordance with the known safety profile of pregabalin.